Argo Biopharma and Novartis Deepen Collaboration, Including Multiple Cardiovascular Products
September 5, 2025
Source: drugdu
127
On September 3, 2025, Argo Biopharma Co., Ltd. announced a new strategic collaboration agreement with Novartis (NYSE: NVS) to jointly develop multiple cardiovascular products. This new agreement expands upon the existing collaboration between the two parties.
Under this agreement, Argo Biopharma granted Novartis an option for ex-China rights to two early-stage molecules for the treatment of severe hypertriglyceridemia (sHTG) and mixed dyslipidemia, as well as a right of first negotiation for BW-00112 (ANGPTL3). This product is currently in Phase II clinical trials in the United States and China, with Argo Biopharma leading the subsequent combination therapy clinical trials. For another preclinical siRNA drug candidate, Argo Biopharma granted Novartis an exclusive ex-China license, including a reciprocal option to share profits and losses (P&L) in the United States and China. This product is expected to initiate Phase I clinical trials in 2026.
https://finance.eastmoney.com/a/202509053505318712.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
